Clinical

Wellness programs that base financial incentives on loss aversion could result in better outcomes, according to a trial of how certain financial incentives impact physician activity among overweight and obese adults.

While patients with chronic obstructive pulmonary disease have a higher risk of stroke than the general population, patients who have frequent exacerbations of their illness actually have a reduced risk of stroke than those with infrequent exacerbations.

A Task Force composed of gastroenterology specialists, with a special interest in colorectal cancer, has released updated recommendations urging post-operative colonoscopy instead of endoscopy to improve survival.

Durvalumab is being developed for the treatment of PD-L1—positive patients with inoperable or metastatic urothelial bladder cancer

What we're reading, February 17, 2016: Pfizer pays to settle Medicaid claims case; needle exchanges will get financial boost with federal funding; and in New Jersey, Chris Christie releases budget that includes steep cuts to hospitals.

Individuals with more than one diagnosis are more likely to report to a primary care physician than to a subspecialty physician.

Whether or not employer wellness programs work remains debated, but the real question to address is whether we are even fighting the right battle.

A collaboration led by CMS and America’s Health Insurance Plans released 7 core sets of quality measures created to reduce complexity, decrease cost burden, and ensure high-quality care.

A noninvasive colorectal cancer screening test manufactured by Exact Sciences, which received CMS coverage within months of its FDA approval, is not included under Humana’s coverage policy

Relatively simple improvements could increase patient satisfaction and potentially improve the important process of imparting patient information during enrollment of cancer patients into clinical trials.

Inhibiting the PIGF/VEGFR-1 signaling regressed tumor growth in obese, but not in lean mice, the author report.

What we're reading, February 15, 2016: despite cuts to the program, enrollment in Medicare Advantage is up 50% over 5 years; orphan drug designations from the FDA up 22% in 2015; and Zika virus infections on the rise in Puerto Rico.

This week in managed care the top stories included President Obama's final budget plan, value-based deals made for Novartis' new heart drug, and a look at the strides made in immuno-oncology.

In the first large-scale study of its kind, researchers at Kaiser Permanente and the University of California San Francisco found that rates of dementia risk vary across racial and ethnic groups.

A study published in Cancer Epidemiology, Biomarkers & Prevention has identified geographic and ethnic factors as an important determinant of vaccinating against the human papillomavirus.

Patients with advanced kidney cancer in the UK now have access to nivolumab through an early access scheme.

What we're reading, February 12, 2016: the former Kentucky governor is looking to block the current governor's plans to dismantle Kynect; Senator Orrin Hatch speaks out against Medicare negotiation of drug prices; and the link between Zika and microcephaly is growing stronger.

Carfilzomib, a proteasome inhibitor, has been approved by the FDA for use in combination with dexamethasone or lenalidomide, in patients with relapsed/refractory multiple myeloma who have previously received 1 to 3 lines of therapy.

A summary of updated breast cancer screening guidelines, MEDPAC recommendations for 340B, and disparity in survival of young patients with Hodgkin lymphoma.

A study published in JAMA Oncology found that the knowledge of genetic risk influenced surgical treatment decisions in women younger than 40 years who were diagnosed with breast cancer.

At the annual JP Morgan Healthcare Conference, Patrick Soon-Shiong, MD, introduced Cancer MoonShot, his vision for a coalition to improve cancer outcomes. His claims on federal support for the project, however, stirred some controversy.

While the number and diversity of immunologically-based anticancer agents have increased dramatically, a number of challenging questions persist: sequencing with existing regimens, selection of best responders, cost, and patient access.

Although the United States is often viewed as having some of the best healthcare in the world, the validity of this assertion has been called into question for a number of years.

Mice administered FOLFIRINOX through the implantable device had greater tumor regression and lower tissue toxicity.

The cost issues with immuno-oncology agents are real, but so is the value that they bring to the table. How can we improve access to these agents at a reasonable cost?